Background and objectives: In recent years, there has been a significant increase in the
prevalence of pulmonary mycosis disease, and its mortality has increased. There are very …

Background: Invasive pulmonary aspergillosis (IPA) remains a life-threatening condition
despite systemic antifungal therapy. Objectives: This retrospective analysis investigated …

Since its discovery, amphotericin B (AmB) became a key management because it is the most
common antifungal drug with activity to disrupt the fungal cell wall. Furthermore, it is the first …

Abstract Background Invasive pulmonary Aspergillus and invasive bronchial aspergillosis is
a life-threatening opportunistic fungal infection that predominantly affects …

Background In recent years, the prevalence of respiratory fungal diseases has increased.
Polyene antifungal drugs play a pivotal role in the treatment of these conditions, with …

Background Pulmonary aspergilloma (PA) is a common complication seen in patients with
pulmonary tuberculosis sequelae. Antifungal therapy, including oral azoles, is commonly …

Fungal diseases are a significant cause of morbidity and mortality worldwide, primarily
affecting immunocompromised patients. Aspergillus, Pneumocystis, and Cryptococcus are …

The aim of this study was to evaluate the efficacy of percutaneous treatment of pulmonary
lesions from invasive aspergillosis in immunocompromised patients. From 1992 to 1998, ten …

Targeted intrapulmonary delivery of drugs may reduce systemic toxicity and improve
treatment efficacy. In the current study, we evaluated the effects of a combination treatment …

Objectives Antifungal monotherapy with polyenes, azoles or echinocandins is not always
effective for invasive pulmonary aspergillosis (IPA). The main purpose of this study was to …